A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms VITALITY-HFpEF
- Sponsors Bayer
- 03 Dec 2018 Planned End Date changed from 15 Jun 2020 to 15 Jan 2020.
- 03 Dec 2018 Planned primary completion date changed from 15 May 2020 to 16 Dec 2019.
- 23 Aug 2018 Planned End Date changed from 28 May 2020 to 15 Jun 2020.